UK-based pet life science and pharmaceutical company Loyal Hound & Co. has announced a $2.3 billion (approximately KRW 3.1 trillion) investment to build manufacturing, logistics, and research hubs in China. The decision is viewed as a proactive response to the rapidly growing pet market in East Asia and part of a long-term strategy to mitigate political and institutional risks in the global supply chain.
The company plans to establish a 120,000㎡ “Pet Life Science Cluster” within a free trade zone near Shanghai. Key facilities will include a production site for high-performance animal formula products, a research institute dedicated to genomics-based longevity prediction algorithms, and a liaison center to collaborate with veterinary schools and hospitals across China.
Rather than focusing on short-term revenue growth, Loyal Hound emphasized that the investment is aimed at securing technological sovereignty and enhancing supply chain independence. The company stated that developing internal capabilities to manage risks in China is crucial to maintaining leadership in the global pet healthcare industry, especially amid continued US-China tensions and shifting European regulations.
As of 2024, China is home to more than 100 million registered pets, and the pet healthcare market is projected to exceed 500 billion yuan (approximately USD 70 billion) by 2025. However, the localization rate of high-function pharmaceuticals and animal formulas remains low, with a heavy dependence on imports. This has exposed structural vulnerabilities in supply stability and product reliability.
To address this issue, Loyal Hound plans to work with China’s veterinary academia to develop a China-specific life data model. The company will design longevity prediction algorithms and customized formulas tailored to the lifestyles of local pet owners. Rather than simply transplanting global technology, the approach is seen as a localized biotech adaptation strategy suited to the Chinese environment.
The investment also reflects a broader effort to internalize risk, particularly in response to China’s technology transfer policies, increased regulatory scrutiny of foreign enterprises, and its national strategy for tech self-reliance. Instead of pursuing a joint venture, Loyal Hound will establish a wholly owned subsidiary, allowing it to integrate production, distribution, and R&D under the control of its UK headquarters. This structure ensures complete ownership and strict control over equity and proprietary technologies.
To protect its core intellectual property, Loyal Hound will operate a dual-core R&D system. The core longevity prediction algorithms will remain encrypted and housed in the UK, while only de-identified data processing and algorithm execution will take place in China.
